VEEA INC. (VEEA) AI Stock Summary

Snapshot

Veea is a tiny edge-computing company with just $222K in FY 2025 revenue, growing 57% but still minuscule in dollar terms. It lost $6.7M for the year and burned $15.5M in free cash flow, while holding only $134K in cash against $19.8M of debt. The company has relied on insider bridge loans, convertible notes, and a fresh at-the-market offering just to stay afloat, and just executed a 1-for-20 reverse split to avoid Nasdaq delisting.

What's Happening Right Now

• Mon 14th Sep '26 · Merger talks: Veea signed a non-binding term sheet to combine with NovaGen Group and launch a health platform, with a $10M cornerstone investment and a management-estimated $750M combined valuation, but no deal terms or dilution figures disclosed yet.
• Thu 10th Sep '26 · Reverse split: Veea completed a 1-for-20 reverse split effective Aug 31, 2026, the maximum ratio shareholders approved, alongside $1.15M in insider bridge notes from CEO-affiliated NLabs.
• Thu 10th Sep '26 · CFO exit: Veea's board terminated CFO Randal Stephenson without cause effective July 31, 2026, installing COO Greg Deisher as acting CFO, alongside $600K in new related-party bridge loans from CEO-affiliated NLabs.
• Wed 9th Sep '26 · Dilution/Liquidity: Veea launched a $4.35M at-the-market stock offering after Nasdaq flagged it for failing the $1 minimum bid price rule, on top of emergency insider loans, convertible notes, and a secured loan facility, describing a survival-financing situation.
• Wed 9th Sep '26 · Earnings/Liquidity: Q2 2026 10-Q showed a $4.0M quarterly net loss, only $887K of unrestricted cash against $14.6M of debt, $11.1M of cash used in operations, and a Nasdaq compliance deadline of Sept 28, 2026 to avoid delisting.

Ownership

Institutions hold 4.2%, insiders hold 4.9%.

Bottom Line

Veea is a micro-cap running on fumes: minimal revenue, heavy losses, almost no cash, and a pattern of insider bridge loans, discounted convertible notes, and a new stock offering just to cover working capital. The reverse split and repeated Nasdaq compliance deadlines point to real listing and liquidity strain, not routine growing pains. A pending, non-binding merger with a private health-tech company adds speculation to an already fragile financial picture, with no disclosed deal terms yet. A reader would need to see actual cash and revenue improve materially before this looks like a stable business.